- €63.33bn
- €71.64bn
- €21.10bn
US stocks weekly: AI reality
Brief: Bio-Techne Co Will Be Required To Pay To Merck KGaA Termination Fee Equal To $230.5 Million If Deal Terminated Under Certain Circumstances - SEC Filing
Press Digest: Financial Times - June 26
US STOCKS-Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
US STOCKS-Nasdaq, S&P end lower as tech megacap declines outweigh upbeat chip outlook
Deals of the day-Mergers and acquisitions
US STOCKS-Nasdaq drops as tech megacap declines outweigh upbeat chip outlook
US STOCKS-Nasdaq drops as tech megacap declines outweigh upbeat chip outlook
US STOCKS-S&P 500, Nasdaq drop as tech megacap declines outweigh upbeat Micron forecast
Deals of the day-Mergers and acquisitions
Bio-Techne soars on $11.3 billion buyout deal from Merck
US STOCKS-Wall St set for higher open after Micron revives AI optimism, upbeat economic data
US STOCKS-Nasdaq futures surge 2% as chip outlook calms AI jitters; inflation data awaited
Advisory: Alerts incorrectly tagged to Merck & Co withdrawn
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Germany's Merck boosts life sciences business with $11 billion bet on Bio-Techne (updated)
Germany's Merck to buy Bio-Techne for $73 per share
Bio-Techne soars on $11.3 billion buyout deal
Brief: Merck Collaborates With Versant Ventures To Launch Saturnus Bio